A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2017
At a glance
- Drugs Lulizumab pegol (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 29 Nov 2017 Status changed from active, no longer recruiting to discontinued.
- 08 Sep 2017 Planned End Date changed from 29 Sep 2017 to 13 Apr 2018.
- 08 Sep 2017 Planned primary completion date changed from 29 Sep 2017 to 1 Oct 2017.